TRIO

Across TCGA pan-cancer cohorts, TRIO mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRIO data layer compared with 27 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRIO mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRIO expression acts as an unfavorable survival marker.

HNSC, PDAC, and LSCC are the cancer types where TRIO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.264	0.886	.002	28	view →
PDAC	DFS	Quartile	All	0.239	0.602	.001	28	view →
LSCC	DFS	Median	All	0.591	0.824	.003	22	view →
COAD	DFS	Median	III,IV	0.822	1.000	.021	18	view →
LUAD	OS	Quartile	All	0.365	1.000	.001	15	view →
CCRCC	OS	Tertile	All	0.625	1.000	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRIO–HNSC (DFS)

Open the HNSC breakdown →